Focus: Biohaven is a publicly traded biotechnology company headquartered in New Haven, CT, focused on small molecules for neurology indications. The company maintains a diversified pipeline spanning neurodegenerative, psychiatric, and orphan neurology disorders.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Biohaven to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Biohaven
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Biohaven's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Serina Therapeutics, Inc. (SER) (CIK 0001708599) — EX-99.1
EX-99.1
8-K Filing: Biohaven Ltd. (BHVN) (CIK 0001935979) — EX-99.1
EX-99.1
Biohaven says FDA roadblocks leave rare disease patients in limbo - Pharma Voice
Biohaven says FDA roadblocks leave rare disease patients in limbo Pharma Voice
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Oric Pharmaceuticals (ORIC) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Oric Pharmaceuticals (ORIC) The Globe and Mail
Piper Sandler reiterates Biohaven stock rating on epilepsy trial - Investing.com
Piper Sandler reiterates Biohaven stock rating on epilepsy trial Investing.com
Biohaven charts comeback path after FDA blow, placing bets on obesity - fiercebiotech.com
Biohaven charts comeback path after FDA blow, placing bets on obesity fiercebiotech.com
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo